Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.

Read Original Copy